HTSUY (Hisamitsu Pharmaceutical Co) EBIT: $156 Mil (TTM As of Nov. 2025)


HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
85 GF Score
Price $2.94
GF Value $5.41
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co EBIT?

Hisamitsu Pharmaceutical Co HTSUY 85 EBIT is $156 Mil as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 85/100 and a GF Value™ of $5.41 (Significantly Undervalued).

Hisamitsu Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2025 was $41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2025 was $156 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hisamitsu Pharmaceutical Co's annualized ROC % for the quarter that ended in Nov. 2025 was 6.41%. Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was 26.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hisamitsu Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was 131.77%.


Hisamitsu Pharmaceutical Co  (OTCPK:HTSUY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hisamitsu Pharmaceutical Co's annualized ROC % for the quarter that ended in Nov. 2025 is calculated as:

ROC % (Q: Nov. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2025 ) + Invested Capital (Q: Nov. 2025 ))/ count )
=115.508 * ( 1 - 21.24% )/( (1425.76 + 1412.141)/ 2 )
=90.9741008/1418.9505
=6.41 %

where

Invested Capital(Q: Aug. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2278.948 - 87.687 - ( 765.501 - max(0, 341.622 - 1322.877+765.501))
=1425.76

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2206.437 - 80.262 - ( 714.034 - max(0, 334.199 - 1260.446+714.034))
=1412.141

Note: The Operating Income data used here is four times the quarterly (Nov. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hisamitsu Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Nov. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2025  Q: Nov. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=163.44/( ( (403.143 + max(222.168, 0)) + (385.849 + max(218.188, 0)) )/ 2 )
=163.44/( ( 625.311 + 604.037 )/ 2 )
=163.44/614.674
=26.59 %

where Working Capital is:

Working Capital(Q: Aug. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(332.035 + 168.77 + 56.571) - (87.687 + 0 + 247.521)
=222.168

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(314.552 + 165.675 + 66.185) - (80.262 + 0 + 247.962)
=218.188

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hisamitsu Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Nov. 2025 )
=156.454/118.733
=131.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co EBIT Related Terms


Hisamitsu Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co EBIT Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.56 121.22 128.36 189.42 152.66

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.25 26.18 42.39 40.86 47.03

HTSUY vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's EV-to-EBIT falls into.


HTSUY
85GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $156 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $156 Mil mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a EBIT of $156 Mil as of Nov. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hisamitsu Pharmaceutical Co.
Is Hisamitsu Pharmaceutical Co's EBIT too high?
Hisamitsu Pharmaceutical Co's current EBIT is $156 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's EBIT compare to ZTS?
Hisamitsu Pharmaceutical Co's EBIT of $156 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hisamitsu Pharmaceutical Co. Hisamitsu Pharmaceutical Co's current EBIT is $156 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.41, compared to a current price of $2.94 — trading 45.7% below its estimated fair value. The current EBIT is $156 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current EBIT is $156 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued. The current stock price of $2.94 is trading 45.7% below its estimated GF Value™ of $5.41. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • EBIT: $156 Mil
  • GF Value™: $5.41 vs. price of $2.94 (45.7% below fair value)
  • GF Score™: 85/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
85GF Score

Get the complete analysis for HTSUY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$5.41
GF Value